切换至 "中华医学电子期刊资源库"
高级检索
中华老年病研究电子杂志

中华老年病研究电子杂志 ›› 2020, Vol. 07 ›› Issue (01) : 41 -46. doi: 10.3877/cma.j.issn.2095-8757.2020.01.010

所属专题： 文献；

综述

快速眼动睡眠行为障碍的治疗
王红1, 侯辰2, 李锐2,†(), 唐鹏2   
  1. 1. 710021　西安医学院
    2. 710068　西安，陕西省人民医院老年神经科
  • 收稿日期:2019-10-25 出版日期:2020-02-28
  • 通信作者: 李锐
  • 基金资助:
    陕西省科技厅社会发展领域项目(2018SF-028); 陕西省中医管理局项目(2019-ZZ-LC002)

Treatment in rapid eye-movement sleep behavior disorder

Hong Wang1, Chen Hou2, Rui Li2,†(), Peng Tang2   

  1. 1. Xi'an Medical University, Xi'an 710021, China
    2. Geriatric Neurology, Shanxi Provincial People's Hospital, Xi'an 710068, China
  • Received:2019-10-25 Published:2020-02-28
  • Corresponding author: Rui Li
  • About author:
    Corresponding author: Li Rui, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王红, 侯辰, 李锐, 唐鹏. 快速眼动睡眠行为障碍的治疗[J]. 中华老年病研究电子杂志, 2020, 07(01): 41-46.

Hong Wang, Chen Hou, Rui Li, Peng Tang. Treatment in rapid eye-movement sleep behavior disorder[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(01): 41-46.

快速眼动睡眠行为障碍（rapid eye-movement sleep behavior disorder, RBD）是一种常见于老年人的睡眠障碍类型，其主要特征为深睡眠时产生复杂的梦境及暴力行为。RBD是多种突触核蛋白病如帕金森病、多系统萎缩等的前驱标志物，早期发现并给予针对性治疗意义重大。目前，RBD的发病机制尚不完全清楚，药物治疗效果也无定论。本文将重点综述RBD的药物和非药物治疗研究进展，旨在为临床预防和治疗突触核蛋白病提供参考。

关键词: 快速眼动睡眠行为障碍, 治疗, 睡眠障碍, 神经保护

Rapid eye movement sleep behavior disorder (RBD) is a common type of sleep disorder in the elderly, which is characterized by complex dreams and violent behaviors during the deep sleep. It is a precursor marker of a variety of synuclein diseases, such as Parkinson's disease, multiple system atrophy and so on. The current pathogenesis of RBD is not fully understood, and there is no final conclusion on the therapeutic effect of the drug therapy. This article will focus on the review of drug and non drug treatment of RBD, in order to provide basis for clinical prevention and treatment of synuclein disease..

Key words: Rapid eye-movement sleep behavior disorder, Treatment, Sleep disorder, Neuroprotection
[1]
Frauscher B, Gschliesser V, Brandauer E, et al. Video analysis of motor events in REM sleep behavior disorder[J]. Mov Disord, 2007, 22(10):1464-7140.
[2]
Wing YK, Lam SP, Li SX, et al. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison[J]. J Neurol Neurosurg Psychiatry, 2008, 79(12):1415-1416.
[3]
Zhang J, Lam SP, Ho CK, et al. Diagnosis of REM sleep behavior disorder by video-polysomnographic study: is one night enough[J]? Sleep, 2008, 31(8):1179-1185.
[4]
Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions[J]. Lancet Neurology, 2016, 15(4):405-419.
[5]
Wichniak A, Wierzbicka A, Walecka M, et al. Effects of Antidepressants on Sleep[J]. Curr Psychiatry Rep, 2017, 19(9):63.
[6]
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications[J]. Chest, 2014, 146(5):1387-1394.
[7]
Pujol M, Pujol J, Alonso T, et al. Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography[J]. Sleep Med, 2017, 40:116-121.
[8]
Rodriguez CL, Jaimchariyatam N, Budur K. Rapid eye movement sleep behavior disorder: A review of the literature and update on current concepts[J]. Chest, 2017, 152(3):650-662.
[9]
Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP[J]. Sleep, 2002, 25(2):120-138.
[10]
Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of REM sleep behavior disorder in the general population[J].Sleep, 2018, 41(2). doi: 10.1093/sleep/zsx197.
[11]
Galbiati A, Verga L, Giora E, et al. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies[J]. Sleep Med Rev, 2019, 43:37-46.
[12]
Iranzo A, Santamaria J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2017, 82(3):419-428.
[13]
Postuma RB, Gagnon JF, Vendette M, et al. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2011, 69(5):811-818.
[14]
Sasai T, Matsuura M, Inoue Y. Electroencephalographic findings related with mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder[J]. Sleep, 2013, 36(12):1893-1899.
[15]
Genier Marchand D, Montplaisir J, Postuma RB, et al. Detecting the cognitive prodrome of dementia with lewy bodies: A prospective study of rem sleep behavior disorder[J]. Sleep, 2017, 40(1). doi: 10.1093/sleep/zsw014.
[16]
Youn S, Kim T, Yoon IY, et al. Progression of cognitive impairments in idiopathic REM sleep behaviour disorder[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8):890-896.
[17]
Ferini-Strambi L, Marelli S, Galbiati A, et al. REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders[J]. Arch Ital Biol, 2014, 152(2-3):129-146.
[18]
中华医学会神经病学分会睡眠障碍学组.中国快速眼球运动睡眠期行为障碍诊断与治疗专家共识[J].中华神经科杂志，2017，50(8):567-571.
[19]
Kunz D, Bes F. Twenty years after: another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging[J]. Neuropsychobiology, 2017, 76(2):100-104.
[20]
Schenck CH, Bundlie SR, Ettinger MG, et al. Chronic behavioral disorders of human REM sleep: A new category of parasomnia[J]. Sleep, 1986, 9(2):293-308.
[21]
Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method[J]. Neurology, 1992, 42(7):1371-1374.
[22]
Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases[J]. Brain, 2000, 123(Pt 2):331-339.
[23]
Hendricks JC, Lager A, O'Brien D, et al. Movement disorders during sleep in cats and dogs[J]. J Am Vet Med Assoc, 1989, 194(5):686-689.
[24]
Shin C, Park H, Lee WW, et al. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial[J]. J Neurol Sci, 2019, 401:81-86.
[25]
Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam[J]. J Clin Sleep Med, 2009, 5(3):235-239.
[26]
McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder[J]. Sleep Med, 2013, 14(3):237-242.
[27]
Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease[J]. Brain, 2007, 130(Pt 11):2770-2788.
[28]
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD)[J]. J Clin Sleep Med, 2010, 6(1):85-95.
[29]
Griebling TL. Re: American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults[J]. J Urol, 2019, 202(3):438.
[30]
Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism[J]. Clin Pharmacokinet, 2002, 41(12):913-958.
[31]
St Louis EK. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects[J]. Curr Neuropharmacol, 2009, 7(2):96-105.
[32]
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition[J]. Clin Pharmacokinet, 2000, 38(1):41-57.
[33]
Brzezinski A. Melatonin in humans[J]. N Engl J Med, 1997, 336(3):186-195.
[34]
Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder[J]. J Sleep Res, 2010, 19(4):591-596.
[35]
Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation[J]. Mov Disord, 1999, 14(3):507-511.
[36]
Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder[J]. Psychiatry Clin Neurosci, 2001, 55(3):267-269.
[37]
Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients[J]. Sleep Med, 2003, 4(4):281-284.
[38]
Kunz D. Melatonin in rapid eye movement sleep behavior disorder: why does it work[J]? Sleep Med, 2013, 14(8):705-706.
[39]
Kunz D, Mahlberg R, Muller C, et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials[J]. J Clin Endocrinol Metab, 2004, 89(1):128-134.
[40]
Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects[J]. Psychopharmacology (Berl), 1996, 126(2):179-181.
[41]
McGrane IR, Leung JG, St Louis EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence[J]. Sleep Med, 2015, 16(1):19-26.
[42]
Arnaldi D, Antelmi E, St Louis EK, et al. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk[J]? Sleep Med Rev, 2017, 36:82-95.
[43]
Seabra ML, Bignotto M, Pinto LR, et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment[J]. J Pineal Res, 2000, 29(4):193-200.
[44]
San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system[J]. Eur Psychiatry, 2008, 23(6):396-402.
[45]
Bonakis A, Economou NT, Papageorgiou SG, et al. Agomelatine may improve REM sleep behavior disorder symptoms[J]. J Clin Psychopharmacol, 2012, 32(5):732-734.
[46]
Shiromani PJ, Gillin JC, Henriksen SJ. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy[J]. Annu Rev Pharmacol Toxicol, 1987, 27:137-156.
[47]
Esaki Y, Kitajima T, Koike S, et al. An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder[J]. J Clin Sleep Med, 2016, 12(5):689-693.
[48]
Di Giacopo R, Fasano A, Quaranta D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease[J]. Mov Disord, 2012, 27(4):559-561.
[49]
Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease[J]. J Clin Sleep Med, 2016, 12(10):1403-1409.
[50]
Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases[J]. Neurology, 2000, 55(6):870-871.
[51]
Yeh SB, Yeh PY, Schenck CH. Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease[J]. J Clin Sleep Med, 2010, 6(2):192-195.
[52]
Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder[J]. Parkinsonism Relat Disord, 2013,19(2):153-157.
[53]
Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series[J]. Sleep Med, 2006, 7(5):418-423.
[54]
Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease[J]. Sleep, 2008, 31(10):1418-1421.
[55]
Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease[J]. CNS Drugs, 2010, 24(11):941-968.
[56]
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis[J]. Drug Saf, 2003, 26(6):439-444.
[57]
Tan SM, Wan YM. Pramipexole in the treatment of REM sleep behaviour disorder: A critical review[J]. Psychiatry Res, 2016, 243:365-372.
[58]
Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series[J]. J Clin Pharm Ther, 2014, 39(5):564-566.
[59]
Kozela E, Juknat A, Vogel Z. Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid[J]. Int J Mol Sci, 2017, 18(8). doi: 10.3390/ijms18081669.
[60]
Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort[J]. Sleep Med, 2011, 12(5):445-453.
[61]
Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK)[J]. Sleep Med, 2010, 11(1):43-48.
[62]
Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease[J]. JAMA Neurol, 2015, 72(6):707-712.
[1] 中华医学会骨科学分会关节外科学组, 广东省医学会骨质疏松和骨矿盐疾病分会, 广东省佛山市顺德区第三人民医院. 中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(06): 751-764.
[2] 许正文, 李振, 侯振扬, 苏长征, 朱彪. 富血小板血浆联合植骨治疗早期非创伤性股骨头坏死[J]. 中华关节外科杂志(电子版), 2023, 17(06): 773-779.
[3] 李培杰, 乔永杰, 张浩强, 曾健康, 谭飞, 李嘉欢, 王静, 周胜虎. 细菌培养阴性的假体周围感染诊治的最新进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 827-833.
[4] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[5] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[6] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[7] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[8] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[9] 杨雪, 张伟, 尚培中, 宋创业, 尚丹丹, 张蔚. 胆囊十二指肠瘘结石经瘘口排出后自愈一例报道[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 707-708.
[10] 孔博, 张璟, 吕珂. 超声技术在复杂腹壁疝诊治中的作用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 670-673.
[11] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗：10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[12] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[13] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号